AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$CBIO

Scalzo Richard William sold $10K of CBIO

Scalzo Richard William (Chief Financial Officer) sold 568 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.90 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Scalzo Richard William
Published Sep 18, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
high confidence
Mentioned
$CBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

The CFO's sale is modest and executed via a pre‑arranged plan, suggesting no urgent market‑moving information.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases that may outweigh the impact of this small sale.

Relevance 2/10Novelty 3/10Timing: filed Sep 18, transaction dated Sep 16

Background

Form 4 filing discloses insider transactions; such filings are routine and often low‑impact.

Company-level read

Ticker impact

$CBIONeutralHigh confidence
Context

CFO Richard Scalzo sold 568 shares for $10,167 via a 10b5-1 plan, reducing his stake to 19,730 shares.

Expected impact

No material price movement expected; possible slight short‑term pressure.

Evidence & confidence

The sale amount is small relative to market cap and typical insider activity; market likely discounts it.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; limited to CBIO shareholders.

Global

None

Counterpoint

What could challenge this read

If the CFO is reducing exposure, it could signal concerns about near‑term performance.

Key entities

  • Company
    Crescent Biopharma, Inc.

    Biopharma company listed on NASDAQ under ticker CBIO.

  • Executive
    Richard William Scalzo

    Chief Financial Officer of Crescent Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

OCT 19
$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com2 min
OCT 16
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com2 min
OCT 15
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com1 min
OCT 15
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K4 min
OCT 6
$CBIOHigh

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

investing.com2 min